Effects of treatment with hCDR1 on SLE manifestations in mice.

aSLE-afflicted (NZB×NZW)F1 mice (10–12 mice per group in 4 independent experiments) were treated with weekly subcutaneous injections of the vehicle, hCDR1, or a control (scrambled peptide) for 10 weeks.
bResults are of sera from mice that were bled after the end of treatment. Dilution of sera 1∶1250.
cStatistical evaluation was based on the Mann-Whitney U test to compare post –treatment effects between the vehicle –treated groups and the remaining treatment groups.
dProteinuria was always measured at about the same time of day and all mice in an experimental cohort were tested together.
eImmune complex deposits (ICD) were assessed at sacrifice.
fp = 0.04, 0.02 and 0.0001 between the control peptide and hCDR1 treated mice for dsDNA specific antibodies, proteinuria and ICD, respectively.